Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Diabetes

Diabetes

Subtypes of Diabetes

Type 2 Diabetes 192 Type 1 Diabetes 35 Prediabetes 21 Diabetic Macular Edema 10 Diabetic Nephropathy 7 Diabetic Ketoacidosis 6 Diabetic Peripheral Neuropathy 4 Diabetic Foot Osteomyelitis 3 Hypoglycemia 3 Glycemic Control 2 New-Onset Diabetes 2 Post-transplant diabetes mellitus 2 Proliferative diabetic retinopathy 2 Diabetic emergencies 1 Diabetic neuropathy 1 Diabetic osteoporosis 1 Diabetic Wound Healing 1 Glycemic management 1 Hyperglycemia in pregnancy 1 Hyperglycemic Crisis 1 Hyperosmolar hyperglycemic state 1 Impaired Awareness of Hypoglycemia 1 Insulin-Dependent Diabetes 1 Non-proliferative diabetic retinopathy 1 Normal Hypoglycemia Awareness 1 Painful diabetic peripheral neuropathy 1 Plantar Diabetic Foot Ulcers 1 Postprandial Hyperglycemia 1 Steroid-induced diabetes 1 Steroid-induced hyperglycemia 1 Type 2 Diabetes Mellitus with Mild Cognitive Impairment 1 Type 3 Diabetes Mellitus 1 Type 3c Diabetes 1 Diabetic Retinal Disease 0 Diabetic sensorimotor polyneuropathy 0 Hemichorea associated with non-ketotic hyperglycemia 0

383 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Diabetes

750 trials tracked for Diabetes: 270 in phase 3 or 4 and 101 with published results. The most-cited published study has 7289 citations.

750Trials tracked
270Phase 3 & 4
0Recruiting
101With published results
Phase distribution
Phase 4 86 Phase 3 184 Phase 2 59 Phase 1 21 Other / NA 400
  1. Phase 3 Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Completed · 7,289 cited
  2. Phase 3 Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes Completed · 6,525 cited
  3. Phase 3 A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes Completed · 1,897 cited
  4. Phase 4 Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus Completed · 1,771 cited
  5. Phase 3 Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes. Completed · 751 cited
  6. Phase 3 Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes Completed · 697 cited
Show 44 more trials
  1. Phase 3 Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus Completed · 582 cited
  2. Phase 3 Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes Completed · 568 cited
  3. Phase 3 A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events Completed · 566 cited
  4. Phase 3 Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes Completed · 469 cited
  5. Phase 3 Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only Completed · 461 cited
  6. Phase 3 Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus Completed · 438 cited
  7. Phase 3 Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes Completed · 437 cited
  8. Phase 3 Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Completed · 415 cited
  9. Phase 3 Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes Completed · 401 cited
  10. Phase 3 Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes Completed · 393 cited
  11. Phase 3 Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo Completed · 389 cited
  12. Phase 3 Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes Completed · 385 cited
  13. Phase 3 Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus Completed · 364 cited
  14. Phase 3 Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes Completed · 362 cited
  15. Phase 3 Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes Completed · 345 cited
  16. Phase 3 Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment Completed · 338 cited
  17. Phase 3 The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes Completed · 329 cited
  18. Phase 3 Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes Completed · 285 cited
  19. Phase 3 Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin Completed · 278 cited
  20. Phase 3 Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus. Completed · 270 cited
  21. Phase 4 Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI Completed · 269 cited
  22. Phase 3 A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes Completed · 253 cited
  23. Phase 3 The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes Completed · 249 cited
  24. Phase 4 Stop Atherosclerosis in Native Diabetics Study Completed · 247 cited
  25. Phase 3 A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes Completed · 220 cited
  26. Phase 3 Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes Completed · 220 cited
  27. Phase 3 A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Completed · 215 cited
  28. Phase 3 A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes Completed · 207 cited
  29. Phase 3 Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes Completed · 207 cited
  30. Phase 4 Reducing Total Cardiovascular Risk in an Urban Community Completed · 192 cited
  31. Phase 3 A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus Completed · 187 cited
  32. Phase 3 Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes Completed · 176 cited
  33. Phase 4 Effect of Testosterone in Men With Erectile Dysfunction Completed · 160 cited
  34. Phase 3 The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy Completed · 134 cited
  35. Phase 3 A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes Completed · 125 cited
  36. Phase 3 A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes Completed · 121 cited
  37. Phase 3 Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Completed · 119 cited
  38. Phase 3 Insulin Resistance Intervention After Stroke Trial Completed · 108 cited
  39. Phase 3 The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy Completed · 106 cited
  40. Phase 3 Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT) Completed · 102 cited
  41. Phase 4 Treatment of Diabetes and Depression in Hispanics and African Americans and Its Effect on A1c and Quality of Life. Completed · 97 cited
  42. Phase 4 Acute Effect of Exenatide on Brain Glucose Metabolism Completed · 95 cited
  43. Phase 3 RCT Metformin for Reduction of Gestational Diabetes Mellitus Effects Completed · 83 cited
  44. Phase 4 Safety and Efficacy of Saxagliptin for Glycemic Control in Non-Critically Ill Hospitalized Patient Completed · 78 cited

Showing the 50 most-cited and recently-updated of 750 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Diabetes: what the trials found

Ertugliflozin (15 mg) was shown to have a modifying effect on blood pressure in patients with diabetes 1. Additionally, the use of antiplatelet agents was associated with significant reductions in LDL cholesterol, systolic blood pressure, and HbA1c levels 20.

Albiglutide (30 mg) demonstrated a statistically significant reduction in the time to first occurrence of Major Adverse Cardiovascular Events (MACE) and the time to MACE or urgent revascularization for unstable angina 17. Liraglutide was shown to influence cortical activation during food visualization regarding desirable versus less desirable food cues 18.

Standard pharmacological management including FDA-approved drugs for blood pressure and cholesterol resulted in significant reductions in LDL cholesterol and blood pressure 19. Sertraline use was associated with a decrease in HbA1c levels and an improvement in quality of life 22. Sildenafil citrate demonstrated improvements in erectile function scores and other related domains 21.

Recent results — preliminary, needs further review

  • - The DASH4D diet significantly reduced systolic blood pressure (p=<0.001) 4.
  • - A Culinary Medicine Program was associated with reductions in HbA1c, BMI, and systolic blood pressure 10.
  • - Specific interventions like the Diabetes Prevention Program were associated with improvements in blood pressure and weight over 6 months 6.
  • - Smart insulin pens combined with CGM showed a reduction in hyperglycemia (HbA1c) 12.
  • - Walking breaks to break up sitting (INT-SIT) were associated with changes in postprandial glucose, triglycerides, and insulin 7.

For the clinician treating this condition

  • Ertugliflozin (15 mg) is established as an intervention that modifies blood pressure in diabetic patients 1.
  • Albiglutide (30 mg) significantly reduces the time to MACE and urgent revascularization for unstable angina 17.
  • Multi-modal approaches, including Culinary Medicine programs and specific dietary interventions like DASH4D, show promise in managing HbA1c and blood pressure [4, 10].

AI synthesis of 12 cited trials, updated Jun 15, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

Diabetes: current evidence & treatments

Diabetes mellitus is associated with a high burden of microvascular and macrovascular complications, including diabetic neuropathy, retinopathy, nephropathy, and peripheral arterial disease, as observed in adult Ugandans 2. Chronic hyperglycemia contributes to multi-level nerve damage across peripheral, autonomic, and central nervous systems, driven by metabolic and vascular disturbances such as oxidative stress and microvascular dysfunction 6. Immunometabolic dysregulation, including activation of the polyol pathway, advanced glycation end products, and mitochondrial dysfunction, creates a pro-inflammatory microenvironment that drives hyperalgesia and hypoesthesia in diabetic peripheral neuropathy 1.

Pharmacological interventions show varying benefits in diabetes management. Semaglutide reduces the risk of kidney decline or death in type 2 diabetes with chronic kidney disease 10 and improves metabolic health in schizophrenia patients on antipsychotics 15. GLP-1 receptor agonists may reduce cognitive decline in type 2 diabetes patients with dementia 13 and are associated with a lower risk of serious liver events compared with DPP-4 inhibitors 25. SGLT2 inhibitors are associated with lower all-cause mortality in heart transplant recipients with type 2 diabetes 3. Evolocumab reduces cardiovascular events in diabetes without known atherosclerosis 16. Metformin is associated with higher lactate concentrations during exercise in adults with prediabetes and type 2 diabetes 8. Insulin degludec/liraglutide ranks highest for HbA1c reduction among fixed-ratio combinations 20. Intravitreal ziv-aflibercept reduces central macular thickness and improves visual acuity in diabetic macular edema 9.

Emerging technologies and genetic insights are advancing diabetes care. Transcriptomic analysis identified 337 high-confidence type 2 diabetes-associated genes in human pancreatic islets, with an IsletDysfunctionScore showing significant separation between non-diabetic and type 2 diabetes islets 5. AI-driven cardiovascular risk prediction in type 2 diabetes shows promise but is limited by bias and lack of diversity 23. Pancreatic tissue engineering for type 1 diabetes faces a vascularization hurdle 7. CAR technology is being explored for type 1 diabetes among other conditions 11. scFv-based biologics show potential for immunomodulation in both type 1 and type 2 diabetes 19. Adipose-derived stem cell exosomes are being investigated for diabetic foot ulcers, but efficacy data are lacking 14.

Key drugs in the evidence

metformin 3 semaglutide 3 rivaroxaban 2 sodium-glucose cotransporter 2 inhibitors 2 statins 2 SGLT2 inhibitors 2 direct oral anticoagulants 2 apixaban 1 envafolimab 1 sodium-glucose cotransporter 2 inhibitor 1

Latest findings

AI-generated synthesis of 17 cited studies, updated Jun 12, 2026. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Meta-analysis finds 23% subthreshold depression prevalence in patients with diabetes mellitus
Diabetes & Endocrinology Meta-analysis
Meta-analysis finds 23% subthreshold depression prevalence in patients with diabetes mellitus Subthreshold depression affects about one in four people with diabetes mellitus
A systematic review and meta-analysis of 33 studies including 255,371 patients with diabetes found a pooled prevalence of subthreshold depre…
About one in four people with diabetes has subthreshold depression, a condition that raises complication risks and lowers quality of life wi…
Apr 9, 2026
Personalized nutrition and behavioral correction address feline obesity and associated comorbidities like diabetes and osteoarthritis
Psychiatry Sys. Review
Personalized nutrition and behavioral correction address feline obesity and associated comorbidities like diabetes and osteoarthritis Review finds personalized nutrition and exercise help manage cat obesity and related health issues
This systematic review evaluated determinants, diagnosis, pathophysiology, and management of obesity in domestic cats.
Personalized nutrition and exercise plans help manage cat obesity, a common disorder that raises risks for diabetes and other serious health…
Frontiers Apr 9, 2026
Subretinal saline injection added to vitrectomy for diabetic macular edema with hard exudates
Ophthalmology RCT
Subretinal saline injection added to vitrectomy for diabetic macular edema with hard exudates Does a simple salt solution injection help eyes with diabetic swelling?
A randomized trial in 56 patients with diabetic macular edema and hard exudates compared vitrectomy with subretinal balanced salt solution i…
A simple salt solution injection under the retina helped patients with diabetic eye swelling see better and reduced fluid buildup within sev…
Apr 9, 2026
Elevated plasma phenylalanine associated with obesity, type 2 diabetes, and cancer risk
Diabetes & Endocrinology Sys. Review
Elevated plasma phenylalanine associated with obesity, type 2 diabetes, and cancer risk High plasma phenylalanine linked to obesity, diabetes, and cancer risk
This systematic review examines epidemiological and mechanistic evidence regarding elevated plasma phenylalanine in metabolic disorders.
High blood phenylalanine is linked to obesity, type 2 diabetes, and cancer risk by blocking insulin signals and damaging mitochondria.
Frontiers Apr 9, 2026
Finerenone linked to improved KDIGO risk categories in T2D and CKD patients
Diabetes & Endocrinology RCT
Finerenone linked to improved KDIGO risk categories in T2D and CKD patients Does finerenone help kidney risk categories improve in diabetes patients compared to placebo?
A post hoc subanalysis of an RCT in patients with type 2 diabetes and chronic kidney disease found finerenone therapy was associated with a …
Patients with diabetes and kidney disease taking finerenone were much more likely to see their kidney risk category improve and less likely …
Apr 9, 2026
Cumulative risk score predicts VBAC success and NICU admission in 477,693 TOLAC attempts
OB/GYN & Women's Health Cohort
Cumulative risk score predicts VBAC success and NICU admission in 477,693 TOLAC attempts Risk Score Predicts VBAC Success and NICU Admission Rates in Large Study
This national validation cohort study examined 477,693 term, singleton deliveries with trial of labor after cesarean (TOLAC) from 2020 to 20…
A new risk score predicts vaginal birth success and NICU admission rates for nearly half a million women attempting labor after a previous C…
medRxiv Apr 9, 2026
Urinary podocin and nephrin show poor short-term prediction of DKD progression in type 2 diabetes
Nephrology Cohort
Urinary podocin and nephrin show poor short-term prediction of DKD progression in type 2 diabetes Could a single urine test predict kidney failure in one year? The answer is no
A retrospective cohort study of 119 adults with type 2 diabetes and DKD found that single baseline measurements of urinary podocin, nephrin,…
Patients with type 2 diabetes cannot rely on a single urine test to predict kidney failure over the next 12 months.
Frontiers Apr 9, 2026
FDA Approves Dapagliflozin Tablets (dapagliflozin) to Reduce Heart Failure Hospitalization Risk and Improve Glycemic Control in Adults with Type 2 Diabetes
Diabetes & Endocrinology FDA Approval
FDA Approves Dapagliflozin Tablets (dapagliflozin) to Reduce Heart Failure Hospitalization Risk and Improve Glycemic Control in Adults with Type 2 Diabetes FDA approves a diabetes drug that also helps protect the heart in certain adults
The FDA has approved dapagliflozin tablets to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus a…
A new diabetes drug is approved to lower blood sugar and cut the risk of heart failure hospitalization in adults with type 2 diabetes and he…
FDA Apr 9, 2026
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Heart Failure Risk Reduction and Glycemic Control in Type 2 Diabetes
Diabetes & Endocrinology FDA Approval
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Heart Failure Risk Reduction and Glycemic Control in Type 2 Diabetes FDA approves a diabetes pill that also helps protect the heart from failure
The FDA has approved dapagliflozin tablets to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and establ…
A new diabetes pill approved by the FDA also lowers the risk of hospitalization for heart failure in adults with type 2 diabetes.
FDA Apr 9, 2026
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Type 2 Diabetes and Heart Failure Risk Reduction
Diabetes & Endocrinology FDA Approval
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Type 2 Diabetes and Heart Failure Risk Reduction FDA approves a new diabetes pill that also helps protect the heart
The FDA has approved dapagliflozin tablets for two indications: to improve glycemic control in adults with type 2 diabetes mellitus, and to …
A new daily diabetes pill now approved by the FDA helps lower blood sugar and reduces the risk of heart failure hospitalization for adults w…
FDA Apr 9, 2026
FDA Approves Dapagliflozin for Reducing Heart Failure Hospitalization Risk and Improving Glycemic Control in Adults with Type 2 Diabetes
Diabetes & Endocrinology FDA Approval
FDA Approves Dapagliflozin for Reducing Heart Failure Hospitalization Risk and Improving Glycemic Control in Adults with Type 2 Diabetes FDA approves a diabetes drug that also helps protect the heart
The FDA has approved dapagliflozin to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and estab…
A new diabetes drug now helps lower blood sugar while also reducing the risk of heart failure hospitalization for adults with heart disease …
FDA Apr 9, 2026
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Heart Failure Risk Reduction and Glycemic Control in Type 2 Diabetes
Diabetes & Endocrinology FDA Approval
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Heart Failure Risk Reduction and Glycemic Control in Type 2 Diabetes FDA approves a diabetes drug that also helps lower the risk of heart failure
The FDA has approved dapagliflozin tablets to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and establ…
A new diabetes pill now helps lower blood sugar and reduces the risk of hospitalization for heart failure in adults with type 2 diabetes.
FDA Apr 9, 2026

Questions about Diabetes

How many pregnant women were in the Lp(a) gestational diabetes risk study?

The Lp(a) gestational diabetes risk study included 922 pregnant women with normal glucose tolerance (NGT) after propensity score matching.

Full answer →
What is the link between diabetes and the immune system fighting tuberculosis?

Diabetes weakens the immune system's ability to control tuberculosis, increasing risk of infection and worse outcomes.

Full answer →
Can surgery help heal wounds caused by gouty tophi in patients with diabetes?

Yes, surgery can help heal wounds from gouty tophi, but diabetes increases the risk of delayed healing and infection, so careful preoperative management is essential.

Full answer →
How does having diabetes affect the risk of infection after spinal surgery?

Yes, diabetes significantly increases the risk of infection after spinal surgery, with studies showing roughly 3-4 times higher odds of surgical site infection.

Full answer →
Can immune checkpoint inhibitors cause diabetes mellitus in patients?

Yes, immune checkpoint inhibitors can cause diabetes mellitus, often presenting suddenly with diabetic ketoacidosis.

Full answer →
Do voltage-dependent potassium channels play a role in diabetes research findings?

Yes, voltage-dependent potassium (Kv) channels help regulate insulin secretion, and their dysfunction is linked to diabetes. Research explores them as potential drug targets.

Full answer →
Does switching to integrase inhibitors increase the risk of developing diabetes in HIV patients?

Yes, switching to integrase inhibitors (INSTIs) is linked to an increased risk of developing diabetes in people with HIV, based on recent studies.

Full answer →
Can Ganoderma lucidum polysaccharides help manage diabetes and related complications?

Yes, Ganoderma lucidum polysaccharides (GLPs) show potential to help manage diabetes and its complications through antioxidant, anti-inflammatory, and blood sugar-lowering effects, but human trials are needed.

Full answer →
See all 8 questions about Diabetes →